| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 15.205 | 11.630 | 13.560 | 34.965 | 26.473 | 27.027 | 29.083 | 38.933 | 36.389 | 36.353 |
| Total Income - EUR | 15.214 | 11.631 | 13.560 | 34.991 | 26.477 | 27.192 | 29.084 | 38.935 | 36.399 | 37.775 |
| Total Expenses - EUR | 8.572 | 18.912 | 13.047 | 16.199 | 18.872 | 21.609 | 21.739 | 20.835 | 24.908 | 35.890 |
| Gross Profit/Loss - EUR | 6.642 | -7.280 | 513 | 18.792 | 7.606 | 5.583 | 7.345 | 18.100 | 11.490 | 1.884 |
| Net Profit/Loss - EUR | 6.185 | -7.629 | 106 | 17.733 | 6.799 | 4.799 | 6.559 | 17.096 | 8.748 | -628 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Vadimonium S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 541 | 272 | 0 | 398 | 129 | 18.057 | 12.942 | 8.594 | 3.983 | 54 |
| Current Assets | 12.610 | 4.861 | 6.025 | 23.265 | 30.177 | 14.845 | 27.141 | 48.946 | 62.602 | 64.677 |
| Inventories | 0 | 0 | 0 | 0 | 370 | 0 | 0 | 0 | 16 | 0 |
| Receivables | 9.963 | 2.857 | 2.250 | 14.295 | 10.423 | 1.648 | 109 | 4.028 | 138 | 215 |
| Cash | 2.647 | 2.003 | 3.775 | 8.970 | 19.384 | 13.197 | 27.032 | 44.918 | 42.232 | 24.255 |
| Shareholders Funds | 12.951 | 4.901 | 4.924 | 22.567 | 28.929 | 33.180 | 39.003 | 56.219 | 64.797 | 63.807 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 200 | 232 | 1.101 | 1.109 | 1.376 | 114 | 1.093 | 1.924 | 1.802 | 1.150 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Vadimonium S.r.l.